As checked in September 2026, established blood-forming transplant uses coexist with narrowly defined cell-medicine approvals and investigational uses. For example, the US FDA approved Ryoncil for steroid-refractory acute graft-versus-host disease in children aged two months and older. That approval is neither a general cure claim nor confirmation of access in Thailand. US FDA: Ryoncil product information. Ask about the exact product, diagnosis and country; this is an example, not a complete list of approved treatments.
On this page
Check the product, indication and jurisdiction
A current claim should include the treatment name, the condition it addresses and the authority responsible for its use. An approval announcement in another country does not establish access in Thailand. Ask for the current product information or research documents, including restrictions and eligibility criteria, rather than relying on the date in a headline.
Questions to take to a consultation
- Which current document supports this claim?
- Does it cover my condition and age group?
- Does it describe the same product and route being offered?
Request clear written answers and discuss unresolved points with a clinician familiar with your history before committing to a product or procedure.
Related questions
- What is the stem cell used for?
- What diseases can be cured by stem cells?
- What things can stem cells cure?
- What is the success rate of stem cell therapy?
Return to the FAQ index to browse all questions and the detailed decision guides.
Ask about an assessment
For questions about the review process, availability or a written estimate, message Thailand Stem Cell Clinic. Ask how to share records securely. An enquiry does not confirm eligibility or that a particular treatment is offered.
All FAQs · Treatment guides · Contact information
Sources and further reading
General information, not an individual medical recommendation. Prices, coverage, eligibility and authorisation require case-specific confirmation. Source links describe their own research and jurisdictions.